Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil , a commercial-stage biopharmaceutical company committed to meeting the...

Related Keywords

United States ,Allschwil ,Switzerland General ,Switzerland ,Basilea ,Basel Stadt ,Swiss ,Nils Schr ,Vanceg Fowler Jr ,Thomas Holland ,Marc Engelhardt ,Adesh Kaul ,David Veitch ,Development Authority ,International Journal Of Antimicrobial Agents ,Swiss Exchange ,Duke University School Of Medicine ,Basilea Pharmaceutica International Ltd ,Drug Administration ,Administration For Strategic Preparedness ,Head Of Corporate Communications Investor Relations ,Us Department Of Health ,Biomedical Advanced Research ,Department Of Medicine ,Basilea Pharmaceutica Ltd ,Human Services ,Pharmaceutica Ltd ,Chief Executive Officer ,Chief Medical Officer ,New Drug Application ,Molecular Genetics ,Duke University School ,Associate Professor ,Chief Financial Officer ,Strategic Preparedness ,Ventilator Associated Bacterial Pneumonia ,Corporate Communications ,Pharmaceutica International Ltd ,England Journal ,Clinical Infectious Diseases ,Antimicrobial Agents ,Product Characteristics ,Mortality Weekly Report ,Infectious Diseases ,Markets ,